BeOne Medicines has shown a willingness to shake things up in recent years. Formerly called BeiGene, the oncology-focused company rebranded its name and image in November.

And while sales for its cancer drug Brukinsa have reached blockbuster heights, BeOne has also poured billions into R&D. To “strengthen” its balance sheet, the company struck an $885 million deal in August with Royalty Pharma, which snagged royalty rights to its commercialized bispecific antibody Imdelltra.

BeOne also redomiciled from the Cayman Islands to Switzerland in May. Citing a favorable trade and tax environment, BeOne isn’t the only pharma company setting up shop in the small city of Basel. Today, we’re looking at the industry’s growing presence in Basel and why many are flocking to the bustling biopharma hub. 

Thanks for reading.